Amazon One Medical GLP-1 Program: What It Is and How It Compares

*Compounded semaglutide is not FDA-approved and is not the same as Ozempic, Wegovy, or any other brand-name semaglutide product. Foundayo (orforglipron) is an FDA-approved medication made by Eli Lilly. This article is for educational purposes only and does not constitute medical advice. Consult your licensed healthcare provider before starting or changing any medication. Individual results vary. Prescriva is a Management Services Organization (MSO) operated by Blue Oak Services LLC. Clinical services are provided by independently licensed providers in our partner network and are not provided by Prescriva directly.*

---

In April 2026, Amazon One Medical launched a national GLP-1 management program offering access to brand-name oral and injectable GLP-1 medications. If you have been researching weight loss options and seen Amazon's program come up, you may be wondering what it offers, what medications are included, how the process works, and how it compares to other options on the market.

This article covers what Amazon One Medical's program includes, what Foundayo (their primary oral GLP-1 offering) is, and how the program compares to telehealth platforms offering injectable compounded semaglutide. The goal is to give you the information you need to have a more informed conversation with your healthcare provider.

What Is Amazon One Medical's GLP-1 Program?

Amazon One Medical launched its national GLP-1 Management Program on April 21, 2026. The program is offered through One Medical, the primary care network Amazon acquired in 2023, with medications fulfilled through Amazon Pharmacy.

The program works as follows: a patient completes an intake process, has a telehealth consultation with a One Medical provider, and receives a prescription for a GLP-1 medication if appropriate. Amazon Pharmacy then fills and ships the medication, with same-day delivery available in approximately 3,000 cities as of mid-2026, expanding to an estimated 4,500 cities by end of year.

What the Program Offers

Amazon One Medical's GLP-1 program currently offers two tiers of medication:

Oral GLP-1 (Foundayo and oral Wegovy): Available at $149 per month cash-pay, or as low as $25 per month with eligible insurance. Foundayo is also expected to become available through Medicare Part D for qualifying beneficiaries in 2026; verify current Medicare coverage and out-of-pocket pricing directly before enrolling.

Injectable GLP-1 (Wegovy and Zepbound): Available at $299 per month cash-pay.

Telehealth renewals are available at $29 for an asynchronous message-based visit or $49 for a video visit. No Amazon Prime or One Medical membership is required to access the program.

One Medical providers prescribe and manage the treatment. Amazon Pharmacy handles fulfillment. The integrated structure is a key feature of the platform: the same company handles the consult, the prescription, and the delivery.

What Is Foundayo (Orforglipron)?

Foundayo is the brand name for orforglipron, a GLP-1 receptor agonist developed by Eli Lilly and Company and approved by the FDA on April 1, 2026, for chronic weight management in adults with a body mass index (BMI) of 30 or above, or 27 or above with at least one weight-related health condition.

Foundayo is a small-molecule compound taken as a once-daily oral pill. This distinguishes it from semaglutide-based GLP-1 medications, which are peptide-based. Peptide molecules are too large to survive digestion intact, which is why semaglutide is administered by injection or, in the case of oral semaglutide (Rybelsus), requires a strict fasting protocol to be absorbed. Orforglipron's small-molecule structure allows it to be absorbed through the gut without those restrictions, and it does not require fasting before taking it.

Once absorbed, orforglipron activates GLP-1 receptors, producing the same core effects seen with other GLP-1 medications: suppression of appetite, slowing of gastric emptying, and improvement in blood sugar regulation.

What the Clinical Evidence Shows

The clinical data supporting Foundayo's FDA approval comes from a Phase 2/3 program. A Phase 2/3 study published in the *New England Journal of Medicine* in November 2025 evaluated orforglipron in adults with obesity and found statistically significant and clinically meaningful reductions in body weight compared to placebo [1].

Foundayo is the newest FDA-approved GLP-1 receptor agonist as of mid-2026. Because it received approval in April 2026, the long-term real-world post-approval dataset is still accumulating. The existing clinical trial data is from controlled research populations, and as with all GLP-1 medications, individual results vary.

Foundayo is available by prescription only, through licensed healthcare providers, at Amazon One Medical, Ro, and LillyDirect.

What Is Compounded Semaglutide?

Compounded semaglutide is a prescription injectable medication prepared by licensed 503A compounding pharmacies. It contains semaglutide as the active ingredient. It is not FDA-approved, is not the same product as Wegovy or Ozempic, and cannot be claimed to have the same clinical profile as those brand-name medications.

Compounded semaglutide is administered as a subcutaneous injection, typically once weekly. The dose is set and adjusted by the prescribing provider based on the individual patient's response, tolerability, and clinical goals. Independently licensed providers in telehealth networks review patient health histories and issue prescriptions when appropriate.

What the Evidence Shows for Semaglutide

The clinical evidence for semaglutide comes from the branded product trials. The STEP 1 trial, published in the *New England Journal of Medicine* in 2021, found that participants taking 2.4 mg once-weekly semaglutide lost a mean of 14.9% of body weight over 68 weeks, compared to 2.4% in the placebo group [2]. This trial data pertains to the branded drug Wegovy and cannot be directly attributed to compounded preparations.

Semaglutide has been in widespread clinical use since 2021, and injectable compounded semaglutide through telehealth platforms has been available at scale since 2022. The real-world experience base with injectable semaglutide as a class is substantially larger than that of orforglipron, which received FDA approval in April 2026.

Key Differences at a Glance

The table below compares Amazon One Medical's primary oral offering (Foundayo) with injectable compounded semaglutide as offered through telehealth platforms. These are two distinct products with different regulatory statuses, mechanisms, and clinical profiles. The goal is to help you understand what each option involves so you can discuss the tradeoffs with your provider.

*Prices are current as of June 2026. Verify all pricing directly with each provider before enrolling. Compounded semaglutide is not FDA-approved. Foundayo is FDA-approved.*

For a deeper look at how orforglipron and compounded semaglutide differ as medications, including their mechanisms, side effect profiles, and clinical trial data, see our detailed comparison: [Foundayo vs. Compounded Semaglutide](/articles/foundayo-orforglipron-vs-compounded-semaglutide).

How to Choose Between Them

The right GLP-1 program depends on your individual health history, preferences, and what your licensed healthcare provider recommends for your situation. There is no universally correct answer, and neither option is a better fit for every patient.

Some patients may prefer Foundayo through Amazon One Medical. If you have a strong preference for oral medication over injections, Foundayo eliminates the needle entirely. If you want an FDA-approved medication and the regulatory certainty that comes with that status, Foundayo meets that standard. Amazon's same-day delivery infrastructure and integrated primary care model may also be appealing to patients who already use Amazon services and want a streamlined, consolidated experience.

Some patients may prefer injectable compounded semaglutide. If you are already on a semaglutide-based regimen and have an established response to that molecule, switching to a different molecule involves starting over with an unknown tolerance and efficacy profile for you personally. Independently licensed providers working with injectable compounded semaglutide can adjust doses upward or downward based on how your body responds, which some patients find clinically useful during titration phases or when managing side effects. For patients who have already determined that injectable semaglutide works for them, continuity may outweigh the appeal of a different format.

Both paths require a prescription from a licensed healthcare provider. Neither is appropriate for self-administration without medical oversight. A telehealth consultation with a licensed provider is the starting point for either option.

What About Other GLP-1 Options?

The GLP-1 landscape expanded considerably in 2025 and 2026, and there are more options available today than there were even twelve months ago.

Brand-name injectable Wegovy (semaglutide, Novo Nordisk): FDA-approved for chronic weight management. Cash-pay pricing typically ranges from $249 to $500 or more per month, depending on platform, plan length, and insurance status. Available through Amazon One Medical at $299/mo, as well as Ro, Hims, and direct pharmacy.

Brand-name injectable Zepbound (tirzepatide, Eli Lilly): A dual GIP/GLP-1 receptor agonist, FDA-approved for chronic weight management. Cash-pay pricing typically ranges from $299 to $450 or more per month depending on platform. Available through Amazon One Medical and other telehealth platforms.

Compounded injectable tirzepatide: Prepared by licensed 503A compounding pharmacies. Not FDA-approved. Available through some telehealth platforms at prices typically ranging from $269 to $399/mo.

The landscape of pricing, platform availability, and insurance coverage for these medications continues to shift. Verifying current pricing directly with each provider is always the right step before enrolling.

The Bottom Line

Amazon One Medical launched a GLP-1 management program in April 2026 that offers FDA-approved oral and injectable medications, integrated primary care, and Amazon Pharmacy fulfillment. Foundayo (orforglipron), the program's primary oral offering, is a newly FDA-approved once-daily pill available at $149 per month cash-pay. It is a meaningfully different molecule from semaglutide, with its own clinical evidence base and a post-approval track record that is still developing.

Injectable compounded semaglutide, offered through telehealth platforms including Prescriva, is not FDA-approved and is not the same product as Wegovy or Ozempic. It has a larger real-world track record, is administered weekly by injection, and involves a provider relationship that can include dose adjustment over time. The right choice between these two paths depends on your health history, preferences, and what your provider recommends.

If you want to learn more about whether injectable compounded semaglutide may be appropriate for your situation, Prescriva's independently licensed providers can review your health history and determine whether you may be a candidate.

---

*This is not medical advice. Consult your licensed healthcare provider before starting, stopping, or changing any medication. Compounded semaglutide is not FDA-approved. Foundayo (orforglipron) is an FDA-approved medication made by Eli Lilly.*

<div className="cta-block"> <h3>Interested in Injectable Compounded Semaglutide?</h3> <p>If you are evaluating your GLP-1 options and want to learn more about personalized injectable semaglutide, Prescriva's independently licensed providers can review your health history and determine whether you may be a candidate. Compounded semaglutide is not FDA-approved.</p> <a href="/start" className="cta-button">See If You Qualify</a> </div>

---

References

1. Wharton S, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. *New England Journal of Medicine*. 2025 Nov 6. [https://pubmed.ncbi.nlm.nih.gov/40960239/](https://pubmed.ncbi.nlm.nih.gov/40960239/)

1. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. *New England Journal of Medicine*. 2021;384(11):989-1002. [https://pubmed.ncbi.nlm.nih.gov/33567185/](https://pubmed.ncbi.nlm.nih.gov/33567185/)